Runx2 and CBFβ are required for the expression of genes that mediate the ability of metastatic breast cancer cells to directly modulate both osteoclast (GM-CSF, IL-11) and osteoblast (sclerostin) function. This evidence concerns the gene CBFB and breast carcinoma.